Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said. FDA has approved blinatumomab, a ...
THOUSAND OAKS, Calif., June 14, 2024 /PRNewswire/ -- Amgen (AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO ® (blinatumomab) for the treatment of adult and ...
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The Food and Drug Administration (FDA) has approved Blincyto ® (blinatumomab) for the treatment of adult and pediatric patients 1 month ...
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free ...
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows ...
Hosted on MSN
Research team including Nobel Prize laureate reveals regulatory immune cell precursors disrupted in severe COVID-19
A research team at The University of Osaka, joined by Professor Shimon Sakaguchi—the latest Nobel Laureate in Physiology or Medicine—has identified a previously uncharacterized subset of immune cells ...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback